We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Double-digit growth in key products, including Tyvaso, Remodulin, Orenitram, and Unituxin, contributed to the financial success. United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a ...

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to ...

The increase in Unituxin revenues resulted from an increase in quantities sold and a price increase. Full Year 2024 Compared to Full Year 2023. Total Tyvaso revenues grew by 31 percent to $1,620.4 ...

This is due to competition from generics. Unituxin's sales also increased by 19% to $61 million. The increase was due to both increased demand and higher prices for the drug. The revenue CAGR in ...

Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi ...